Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-ANG3 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALN-ANG3 + evinacumab | EXPERIMENTAL | This arm has been closed |
| ALN-ANG3 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ALN-ANG3 | DRUG | Administered per the protocol |
| Evinacumab | DRUG | No longer being administered |
| Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Medical history of type 2 diabetes and receiving medical therapy or lifestyle interventions for glucose management 2. Hemoglobin A1C (HbA1c) of 6.5 to 10% at screening 3. eGFR 30 to 90 mL/min/1.73 m\^2 using 2021 Chronic Kidney Disease-Epidemiology Collaboration-Estimated...
ALN-ANG3 is an investigational small molecule being developed by Regeneron Pharmaceuticals for diabetic kidney disease. It is in Phase 2 clinical development and is designed to target ANGPTL3. It has not been approved by the FDA and remains under clinical study in adults with diabetic kidney disease.
ALN-ANG3 is being studied for the treatment of diabetic kidney disease (DKD) in adults. The ongoing Phase 2 trial enrolls adult participants with DKD to assess the effects of the drug. It is investigational and has not been approved for any indication.
ALN-ANG3 targets ANGPTL3, also known as angiopoietin-like protein 3. By acting on this molecular target, the small molecule is being evaluated for its effects in adults with diabetic kidney disease. The precise clinical impact of ANGPTL3 targeting in DKD is still being studied in Phase 2.
Regeneron Pharmaceuticals, Inc. is developing ALN-ANG3. Regeneron trades on the Nasdaq under the ticker symbol REGN. The company is running the Phase 2 clinical program evaluating the drug in adults with diabetic kidney disease.
ALN-ANG3 is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. The Phase 2 program is currently recruiting participants with diabetic kidney disease, and no trials of the drug have been completed to date.
ALN-ANG3 is being evaluated in one active clinical trial, NCT07271186, titled a study to assess the effects of ALN-ANG3 in adult participants with diabetic kidney disease. The Phase 2 trial is recruiting, is randomized, double-blind, and placebo-controlled, and plans to enroll 195 participants in the United States.